HC Wainwright Has Pessimistic Outlook of ACRS Q3 Earnings

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Stock analysts at HC Wainwright dropped their Q3 2026 earnings per share (EPS) estimates for shares of Aclaris Therapeutics in a research note issued on Monday, August 10th. HC Wainwright analyst R. Selvaraju now expects that the biotechnology company will post earnings per share of ($0.15) for the quarter, down from their previous forecast of ($0.11). The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Aclaris Therapeutics’ Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.62) EPS, Q1 2027 earnings at ($0.15) EPS, Q2 2027 earnings at ($0.13) EPS, Q3 2027 earnings at ($0.15) EPS, Q4 2027 earnings at ($0.17) EPS and FY2027 earnings at ($0.60) EPS.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. The company had revenue of $1.63 million for the quarter, compared to analyst estimates of $1.38 million. Aclaris Therapeutics had a negative return on equity of 61.65% and a negative net margin of 921.50%.

Other equities analysts also recently issued research reports about the company. Oppenheimer initiated coverage on Aclaris Therapeutics in a research report on Thursday, April 16th. They set an “outperform” rating and a $10.00 price target for the company. Lifesci Capital initiated coverage on shares of Aclaris Therapeutics in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $13.00 price objective on the stock. Wall Street Zen raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Piper Sandler raised their target price on shares of Aclaris Therapeutics from $7.00 to $11.00 and gave the company an “overweight” rating in a research report on Tuesday, May 5th. Finally, Wedbush lifted their price target on shares of Aclaris Therapeutics from $8.00 to $10.00 and gave the company an “outperform” rating in a research note on Wednesday, April 29th. Three investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $11.50.

Aclaris Therapeutics Stock Performance

NASDAQ:ACRS opened at $5.92 on Wednesday. The stock has a 50-day simple moving average of $5.19 and a 200 day simple moving average of $4.36. Aclaris Therapeutics has a 52-week low of $1.58 and a 52-week high of $6.51. The company has a market cap of $827.73 million, a PE ratio of -10.21 and a beta of 0.78.

Institutional Trading of Aclaris Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in Aclaris Therapeutics in the second quarter valued at $53,096,000. Deutsche Bank AG bought a new stake in shares of Aclaris Therapeutics in the 2nd quarter valued at about $5,507,000. Bank of New York Mellon Corp acquired a new stake in Aclaris Therapeutics in the 2nd quarter valued at about $1,495,000. State of Wyoming bought a new position in Aclaris Therapeutics during the second quarter worth about $145,000. Finally, Walleye Capital LLC acquired a new position in Aclaris Therapeutics during the second quarter worth approximately $104,000. 98.34% of the stock is owned by institutional investors.

Key Stories Impacting Aclaris Therapeutics

Here are the key news stories impacting Aclaris Therapeutics this week:

• Positive Sentiment: Wall Street’s consensus price target indicates approximately 69.2% potential upside for ACRS. The report notes that estimate revisions can be more useful than price targets, but the sizable implied upside remains a potential source of investor interest. Wall Street Analysts Believe Aclaris Could Rally 69.2%
• Neutral Sentiment: Reported short interest was listed at zero shares as of August 11, unchanged from the prior period. Because the data show no measurable short position, short-covering activity is unlikely to be a meaningful near-term catalyst.
• Negative Sentiment: HC Wainwright lowered its FY2026 EPS forecast to a loss of $0.62 from $0.49 and reduced its FY2027 forecast to a loss of $0.60 from $0.51. The firm also cut estimates for multiple quarters, including Q3 2026 to $(0.15) from $(0.11), Q4 2026 to $(0.16) from $(0.10), and Q1 2027 to $(0.15) from $(0.11). These revisions point to weaker expected profitability and could pressure the stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.